| Title |
National trends in intestinal resection for Crohn’s disease in the post-biologic era
|
|---|---|
| Published in |
International Journal of Colorectal Disease, April 2013
|
| DOI | 10.1007/s00384-013-1698-5 |
| Pubmed ID | |
| Authors |
John P. Burke, Yoga Velupillai, P. Ronan O’Connell, J. Calvin Coffey |
| Abstract |
Prior international datasets have demonstrated equivocal results in the rate of surgical procedures for the treatment of Crohn's disease (CD) following the introduction of biologic medications. The first biologic medication licensed for use in the Republic of Ireland (ROI) was infliximab in 1999. The current study examined national trends in intestinal resection for CD in the ROI following the introduction of biologic medications. |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| Unknown | 34 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 26% |
| Other | 5 | 14% |
| Student > Postgraduate | 5 | 14% |
| Professor > Associate Professor | 3 | 9% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 4 | 11% |
| Unknown | 7 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 63% |
| Computer Science | 2 | 6% |
| Unspecified | 1 | 3% |
| Sports and Recreations | 1 | 3% |
| Engineering | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 8 | 23% |